Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
3.800
-0.290 (-7.09%)
Nov 13, 2026, 4:00 PM EST - Market closed

Camp4 Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
5.323.50.650.35-
Revenue Growth
39.93%436.50%86.29%--
Cost of Revenue
40.2738.238.8240.6234.1
Gross Profit
-34.95-34.7-38.17-40.27-34.1
Selling, General & Admin
17.8117.3614.9211.6110.23
Research & Development
----0.68
Operating Expenses
17.8117.3614.9211.6110.91
Operating Income
-52.76-52.06-53.09-51.88-45
Interest Expense
----0.03-
Interest & Investment Income
3.412.171.332.810.9
Other Non Operating Income (Expenses)
-71.26-30.02-0.03-0.19-0.1
EBT Excluding Unusual Items
-120.61-79.91-51.79-49.29-44.19
Asset Writedown
-0.49-0.49---
Pretax Income
-121.1-80.4-51.79-49.29-44.19
Net Income
-121.1-80.4-51.79-49.29-44.19
Net Income to Common
-121.1-80.4-51.79-49.29-44.19
Net Income Growth
-----
Shares Outstanding (Basic)
6230500
Shares Outstanding (Diluted)
6230500
Shares Change
193.11%547.76%1087.44%26.47%-
EPS (Basic)
-1.95-2.65-11.04-124.79-141.51
EPS (Diluted)
-1.95-2.65-11.04-124.79-141.51
EPS Growth
-----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
-26.41-29.83-46-44.83-42.57
Free Cash Flow Per Share
-0.42-0.98-9.81-113.51-136.31
Operating Margin
-991.77%-1488.31%-8142.33%-14822.57%-
Profit Margin
-2276.34%-2298.54%-7943.40%-14083.14%-
Free Cash Flow Margin
-496.39%-852.83%-7055.67%-12809.43%-
EBITDA
-50.83-50.42-51.39-50.2-44.12
D&A For EBITDA
1.931.641.71.680.88
EBIT
-52.76-52.06-53.09-51.88-45
SEC Filings: 10-K · 10-Q